American International Group Inc. increased its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 9.1% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 91,020 shares of the medical equipment provider’s stock after buying an additional 7,591 shares during the quarter. American International Group Inc. owned about 0.21% of ABIOMED worth $15,346,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in ABMD. BlackRock Inc. raised its position in shares of ABIOMED by 3.2% in the second quarter. BlackRock Inc. now owns 3,373,655 shares of the medical equipment provider’s stock worth $483,444,000 after acquiring an additional 103,410 shares during the period. Vanguard Group Inc. raised its position in shares of ABIOMED by 1.6% in the second quarter. Vanguard Group Inc. now owns 3,317,593 shares of the medical equipment provider’s stock worth $475,411,000 after acquiring an additional 51,055 shares during the period. Baillie Gifford & Co. raised its position in shares of ABIOMED by 0.3% in the third quarter. Baillie Gifford & Co. now owns 1,976,961 shares of the medical equipment provider’s stock worth $333,316,000 after acquiring an additional 5,271 shares during the period. Palo Alto Investors LLC raised its position in shares of ABIOMED by 1.6% in the second quarter. Palo Alto Investors LLC now owns 1,951,284 shares of the medical equipment provider’s stock worth $279,619,000 after acquiring an additional 29,800 shares during the period. Finally, State Street Corp raised its position in shares of ABIOMED by 2.3% during the 2nd quarter. State Street Corp now owns 1,071,191 shares of the medical equipment provider’s stock worth $153,502,000 after purchasing an additional 23,933 shares during the last quarter. 90.74% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms recently weighed in on ABMD. Zacks Investment Research upgraded shares of ABIOMED from a “hold” rating to a “buy” rating and set a $220.00 price target for the company in a research report on Tuesday, November 7th. Jefferies Group LLC upped their price target on shares of ABIOMED from $175.00 to $208.00 and gave the stock a “buy” rating in a research report on Friday, September 29th. Piper Jaffray Companies restated a “buy” rating and set a $160.00 price target on shares of ABIOMED in a research report on Tuesday, August 29th. BidaskClub upgraded shares of ABIOMED from a “hold” rating to a “buy” rating in a research report on Thursday, August 10th. Finally, BTIG Research reaffirmed a “hold” rating on shares of ABIOMED in a research note on Sunday, October 29th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $185.38.

In other ABIOMED news, Director Eric A. Md Rose sold 982 shares of the stock in a transaction that occurred on Wednesday, August 30th. The shares were sold at an average price of $145.17, for a total transaction of $142,556.94. Following the sale, the director now directly owns 13,634 shares in the company, valued at approximately $1,979,247.78. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, VP Michael G. Howley sold 10,000 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $178.64, for a total transaction of $1,786,400.00. Following the sale, the vice president now owns 56,757 shares in the company, valued at $10,139,070.48. The disclosure for this sale can be found here. In the last three months, insiders sold 28,628 shares of company stock valued at $4,978,890. Corporate insiders own 7.00% of the company’s stock.

Shares of ABIOMED, Inc. (NASDAQ:ABMD) opened at $199.74 on Friday. ABIOMED, Inc. has a one year low of $103.53 and a one year high of $200.00. The company has a quick ratio of 5.20, a current ratio of 5.84 and a debt-to-equity ratio of 0.02. The firm has a market cap of $8,792.82, a P/E ratio of 127.47, a PEG ratio of 2.65 and a beta of 0.23.

ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings results on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.16. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The business had revenue of $132.80 million during the quarter, compared to analysts’ expectations of $131.18 million. During the same quarter in the prior year, the company posted $0.20 EPS. The business’s revenue for the quarter was up 28.9% on a year-over-year basis. sell-side analysts forecast that ABIOMED, Inc. will post 2.38 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “ABIOMED, Inc. (ABMD) Shares Bought by American International Group Inc.” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/abiomed-inc-abmd-shares-bought-by-american-international-group-inc/1725065.html.

ABIOMED Profile

ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.

Want to see what other hedge funds are holding ABMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ABIOMED, Inc. (NASDAQ:ABMD).

Institutional Ownership by Quarter for ABIOMED (NASDAQ:ABMD)

Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.